109,328 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. bought a new position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) during the second quarter, according to its most recent filing with the SEC. The firm bought 109,328 shares of the company’s stock, valued at approximately $3,798,000. E Fund Management Co. Ltd. owned approximately 0.23% of ArriVent BioPharma as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Dynamic Technology Lab Private Ltd bought a new stake in ArriVent BioPharma during the 1st quarter worth approximately $266,000. Woodline Partners LP lifted its holdings in shares of ArriVent BioPharma by 0.4% in the first quarter. Woodline Partners LP now owns 146,373 shares of the company’s stock valued at $2,706,000 after purchasing an additional 576 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of ArriVent BioPharma during the first quarter valued at approximately $189,000. Legal & General Group Plc boosted its position in shares of ArriVent BioPharma by 8.8% during the second quarter. Legal & General Group Plc now owns 14,790 shares of the company’s stock valued at $322,000 after buying an additional 1,197 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in ArriVent BioPharma during the second quarter worth $206,000. Institutional investors and hedge funds own 9.48% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. BTIG Research reaffirmed a “buy” rating and set a $42.00 price target on shares of ArriVent BioPharma in a research report on Thursday, August 13th. Truist Financial upped their price objective on ArriVent BioPharma from $43.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, May 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ArriVent BioPharma in a research report on Friday, July 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ArriVent BioPharma in a research note on Friday, May 22nd. Finally, Citigroup cut their price target on shares of ArriVent BioPharma from $43.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, August 13th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.86.

Key Headlines Impacting ArriVent BioPharma

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $47 price target for ArriVent BioPharma (AVBP), indicating confidence in the company’s long-term potential and significant potential upside. HC Wainwright Forecasts Strong Price Appreciation for ArriVent BioPharma Stock
• Neutral Sentiment: HC Wainwright expects continued losses through 2027, forecasting EPS of approximately ($1.11) in the first quarter, ($1.16) in the second quarter, ($1.04) in the third quarter and ($0.93) in the fourth quarter of 2027. The estimates suggest profitability remains several quarters away.
• Negative Sentiment: HC Wainwright lowered its Q3 2026 EPS forecast to ($1.04) from ($0.96), its Q4 2026 forecast to ($1.07) from ($0.99), and its full-year 2026 forecast to ($4.14) from ($3.86). The downward revisions indicate analysts expect heavier losses than previously projected.

ArriVent BioPharma Stock Up 0.1%

AVBP stock opened at $30.02 on Thursday. The stock has a 50-day simple moving average of $31.74 and a two-hundred day simple moving average of $28.00. ArriVent BioPharma, Inc. has a twelve month low of $17.00 and a twelve month high of $35.83. The firm has a market capitalization of $1.48 billion, a PE ratio of -8.29 and a beta of 1.36.

ArriVent BioPharma (NASDAQ:AVBP) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.06). On average, equities research analysts anticipate that ArriVent BioPharma, Inc. will post -4.01 EPS for the current fiscal year.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.